ବ୍ଲଡ୍ କ୍ୟାନ୍ସର (AML ଲ୍ୟୁକେମିଆ)
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
କେଉଁଠିକୁ ଯିବେ
ଏହି ମେଡିକାଲ୍ ଷ୍ଟଡି ପାଇଁ ଭାରତରେ ୧୧ଟି ହସ୍ପିଟାଲ୍ ରୋଗୀଙ୍କୁ ନେଉଛନ୍ତି।
ରେଜିଷ୍ଟ୍ରି ସାରାଂଶ (ଟେକ୍ନିକାଲ୍)
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo standard induction therapy, the current standard of care. This study will assess the change in disease activity and adverse events in adult participants with acute myeloid leukemia (AML) being treated with of the combination of azacitidine and venetoclax, in India. The combination of azacitidine and venetoclax is being evaluated in the treatment of acute myeloid leukemia (AML). Participants will receive azacitidine with increasing d…
ସ୍ପନ୍ସର: AbbVie
ClinicalTrials.gov ରେ NCT07044687
ରେଜିଷ୍ଟ୍ରିରେ ଶେଷ ଅପଡେଟ୍ 11 Sep 2026 · ଆମ ଦ୍ୱାରା ପଢ଼ାଯାଇଛି 20 Oct 2026